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Gastric cancer although occurring in reduced frequency is still an important disease, 
partly because of the bad prognosis when occurring in western countries. This decline 
in occurrence may mainly be due to the reduced prevalence of Helicobacter pylori (Hp) 
infection, which is the most important cause of gastric cancer. There exist many different 
pathological classifications of gastric carcinomas, but the most useful seems to be 
the one by Lauren into intestinal and diffuse types since these types seldom transform 
into the other and also have different epidemiology. During the nearly 30  years that 
have passed since the groundbreaking description of Hp as the cause of gastritis and 
gastric cancer, a continuous search for the mechanism by which Hp infection causes 
gastric cancer has been done. Interestingly, it is mainly atrophic gastritis of the oxyntic 
mucosa that predisposes to gastric cancer possibly by inducing hypoacidity and hyper-
gastrinemia. There are many arguments in favor of an important role of gastrin and its 
target cell, the enterochromaffin-like cell, in gastric carcinogenesis. The role of gastrin 
in gastric carcinogenesis implies caution in the long-term treatment with inhibitors of 
gastric acid secretion inducing secondary hypergastrinemia, in a common disease like 
gastroesophageal reflux disease.
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Gastric cancer has been one of the most prevalent cancers and combined with a high mortality, 
gastric cancer has been among the leading causes of cancer death. However, there has been a continu-
ous decline in the prevalence of gastric cancers during the last decades. Unfortunately, in spite of 
widespread use of upper gastrointestinal endoscopy, the prognosis in patients affected in the western 
world has not been much improved. This is in contrast to Japan where gastric cancer often is diag-
nosed at an early phase allowing removal and a better prognosis (1, 2). This is partly due to special 
screening programs in Japan having a high prevalence of gastric cancer (1, 2), resulting in diagnoses 
at a curable stage. In most western countries, the prevalence is much lower (3), and therefore, no 
such program has been implemented. The cause of the geographical differences in the prevalence of 
gastric cancer most probably is increased prevalence of Helicobacter pylori (Hp) in East Asia as well 
as a higher frequency of atrophic oxyntic gastritis (4). The prognosis of gastric cancer is better in 
patients from East Asia even when living in the west possibly due to less aggressive biology (5). In 
this review, we will focus on the role of gastrin in the etiology of gastric cancer and at the same time 
give an explanation of the decline in frequency. We will only cover cancers originating from epithelial 
cells (carcinomas) and will not discuss the importance of Epstein–Barr virus that plays a role neither 
in gastric carcinogenesis (6) nor in human papilloma virus, which has a less established impact (7).
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THe GASTRiC MUCOSA
The mucosa of the stomach has traditionally been divided into three 
parts: the cardiac, the oxyntic, and the antral mucosa. During the 
last decades, it has, however, been discussed whether the cardiac 
mucosa occurs normally or represents metaplastic mucosa (8, 9). 
In the oxyntic mucosa, the highly specialized glands contain the 
acid-producing parietal cell, the pepsinogen-producing chief cell, 
and the regulatory, histamine-producing [enterochromaffin-like 
(ECL)] cell, which are specific for the oxyntic glands. These cells 
are not found in the antral glands where instead the gastrin-
producing G-cell is localized. Previously, a sharp border between 
the oxyntic and antral mucosa was presumed, but recent work 
has shown that there is overlap with oxyntic glandular elements 
occurring in the antral mucosa (10). Nevertheless, taking into 
consideration the differences between the oxyntic and the antral 
mucosa, it should be obvious that gastric carcinomas should be 
classified anatomically according to mucosa of origin and not as 
presently only into cardiac and distal carcinomas with the latter 
comprising both oxyntic and antral starting point.
eMBRYOLOGY OF THe GASTRiC 
MUCOSA
The gastrointestinal tract is derived from the endoderm. Stem 
cells located at the neck of the glands divide and differentiate 
into specialized cells while moving into the crypts of the glands 
(parietal and chief cells) or to the surface becoming specialized 
cells producing mucus and bicarbonate, which make the gastric 
mucosa like the mucosa of the duodenal bulb, able to resist 
the highly acidic and proteolytic gastric juice. There are many 
regulatory neuroendocrine (NE) cells in the gastric mucosa. The 
NE cells in man were previously claimed not to divide (11) in 
contrast to similar cells in rodents (12, 13). Now it is, however, 
established that NE cells also in man do divide as shown for the 
β-cell (14) and indirectly for the gastric ECL cell by the selective 
and concentration-dependent trophic effect by gastrin (15). In 
the gastric mucosa, the ability to self-replicate is unique to the 
ECL cell and probably the other NE cells and in contrast to other 
mucosal cells that are formed by differentiation of cells originat-
ing from stem cells. Nevertheless, studies have indicated that 
also the NE cell originate from a common stem cell (16, 17), and 
thus not coming from the neural crest as proposed by Pearse and 
Polak (18) based on the similarities between NE cells at different 
locations and neural cells. Although there seems to be rather firm 
evidence for stem cell origin of NE cells in the intestine and the 
antrum (16, 19), this has not been convincingly shown for NE 
cells in the oxyntic mucosa.
PROPeRTieS OF Ne CeLLS
Whatever the embryology, the NE cells have a unique position 
among the mucosal cells in their ability to divide. Moreover, they 
produce signal substances that affect the function of neighboring 
cells. The signal substances are delivered via a paracrine route 
or via synaptic-like transmission from neuron-resembling 
projections (20, 21) or reaching cells via the blood working as 
hormones. The NE cells have secretory granules that may be 
detected by the general markers belonging to the chromogranins 
(22), and by cell-specific signal substances such as gastrin, ghre-
lin, somatostatin, enteroglucagon, and many others. Interestingly 
from an embryological point of view, the synaptic vesicle marker 
synaptophysin (23) is found in NE cells in common with neurons. 
In the gastrointestinal tract, there are about 30–40 different NE 
cells producing separate signal substances. Although the differ-
ent types of NE cells look quite similar, most of the NE tumors 
originate from only a few of them, typically the ECL cell in the 
stomach and the enterochromaffin (EC) cell in the gut. The 
reason for this discrepancy in tumourigenecity is not known, but 
could be related to differences in growth regulation as well as to 
different signal substances with different effect on surrounding 
tissue. Thus, not only the function (24) but also the proliferation 
(25) of the ECL cell in the stomach is regulated by the hormone 
gastrin. Gastrin is often elevated in gastric hypoacidity either due 
to atrophic gastritis (26) or drug treatment (27). Moreover, the 
signal substance of the ECL cell is histamine having profound 
vascular effects, which presumably may favor invasion and 
spread. In the small intestine, the serotonin-producing EC cell 
is the principal cell of origin of NE tumors. The regulation of the 
EC cell function and proliferation is mainly unknown, but it is 
possible that the serotonin production via its vascular effects is 
the cause of invasion and spread at an early phase, which is in 
many ways a hallmark of this tumor. Although the NE cells do 
proliferate, they do so very slowly which was the background for 
the dispute whether they divide or not (11, 28). The slow prolif-
eration of normal NE cells is reflected in the relatively benign 
course of NE tumors where the patient may live asymptomatically 
for more than a decade with such a tumor or the first metastasis 
may manifest itself after more than two decades.
PReDiSPOSiNG CONDiTiONS FOR 
GASTRiC CANCeR
Gastritis with metaplasia has for long been known to predispose 
to gastric cancer (29). In fact, it was shown that gastric cancer 
virtually only occurred in stomachs with gastritis (29). When 
Hp was shown to be the cause of most types of gastritis (30), it 
was natural to examine the role of Hp in gastric cancer, and it 
was soon shown to be the most important etiological factor of 
this malignancy (31). Very recently, a meta-analysis showed that 
Hp eradication reduced the risk of gastric cancer (32). However, 
also the other type of gastritis, the so-called autoimmune gastritis 
affecting only the oxyntic mucosa predisposes to gastric cancer 
(33). Thus, it seems that the gastritis and not Hp itself is the 
carcinogenic mechanism. Nevertheless, throughout the 25 years 
since the description of Hp as the cause of gastritis (30) and 
gastric carcinoma (31), there have been numerous studies on 
the mechanism by which Hp induces gastric carcinoma, all of 
them without success. When Hp gastritis is confined to the antral 
mucosa, it predisposes to duodenal ulcer (34), but not to gastric 
carcinoma. On the contrary, it is well known that duodenal ulcer 
in a way protects against development of gastric carcinoma (35). 
The risk of gastric carcinoma increases only when the gastritis 
affects the oxyntic mucosa (36) and mainly when oxyntic atrophy 
FiGURe 1 | The gradual transition of an enterochromaffin-like (eCL) 
cell into a highly malignant carcinoma cell of gastric carcinoma of 
diffuse type [from waldum et al. (57) with permission].
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has developed (36). The presence of oxyntic gastric atrophy 
may indirectly be assessed by low serum pepsinogen I (37) 
and even better when combined with determination of gastrin 
(38). In atrophic gastritis, intestinal metaplasia may with time 
develop (39). Intestinal metaplasia has been associated with an 
additional cancer risk but could also just reflect long-standing 
oxyntic atrophy as patients with intestinal metaplasia are older 
than those with oxyntic atrophy without intestinal metaplasia (39, 
40). Anyhow, the sequence in gastric carcinogenesis postulated 
by Correa where the mucosa goes through phases of gastritis, 
atrophic gastritis, intestinal metaplasia, dysplasia of different 
degrees, and finally neoplasia has had great impact for a long 
time (41). However, in a recent Swedish study, there was little 
difference in risk of gastric cancer between patients with atrophic 
gastritis and those with intestinal metaplasia (42). As in other 
parts of the gastrointestinal tract, polyps in the stomach may 
predispose to gastric carcinomas, although the polyp carcinoma 
sequence in the stomach is much less typical than in the colon. 
Typically, the adenomatous polyps, which are rather seldom, are 
the polyps with the highest malignant potential. To be complete, 
it has to be added that ECL cell-derived neuroendocrine tumors 
(NETs) are associated with both Hp infectious gastritis (43) and 
autoimmune gastritis (44). Mutation in the gene CDH1 coding 
for E-cadherin predisposes to gastric carcinoma of diffuse type 
(45), and quite recently missense mutation of one of the genes of 
the proton pump, resulting in anacidity from birth was reported 
to give ECL cell-derived NETs of different degree of malignancy 
at an early age (46, 47).
CLASSiFiCATiON OF GASTRiC 
CARCiNOMAS
Quite recently, a molecular classification of gastric carcinomas 
based on occurrence of mutations was described (48). Although 
such a system may have impact on the choice of treatment at 
the time of classification, it may not tell much about the cell of 
origin, which is mandatory for understanding of carcinogenesis 
and prophylaxis of tumors. In that respect, older histological 
classifications may be more useful.
There are many classification systems for gastric carcinomas, 
but the system proposed by Lauren seems to be the most relevant 
(49). Thus, his classification into intestinal and diffuse types 
where the intestinal type shows glandular structures, whereas the 
diffuse type lacks such differentiation is increasingly used most 
likely because the carcinomas do not transform into each other 
over time (49). In fact, the stable phenotype of the carcinomas 
during the course of the disease may suggest important biological 
differences that are supported by different epidemiology for the 
types of cancer (50). The main weakness with Lauren’s classifica-
tion is that about 15% of the carcinomas are difficult to classify 
due to overlapping traits (49). Although gastric carcinomas 
of diffuse type lack a hallmark of adenocarcinomas (glandular 
growth pattern), they have nevertheless been classified as adeno-
carcinomas due to presumed mucin content of the cancer cells 
(49). The presence of mucin has been based on PAS positivity. 
However, PAS positivity is an unspecific histochemical method 
reacting with glycoproteins/peptides in general (51), and we 
have shown that the diffuse gastric carcinomas with the highest 
content of PAS positive material, the signet ring cells, are positive 
for NE markers both by immunohistochemistry (52) and in situ 
hybridization (53). In general, gastric carcinomas of diffuse type 
often show NE differentiation (54, 55), and it might be that this 
type actually is a NE carcinoma (Figure  1). In this context, it 
should be recalled that it has for long been known that NETs 
(formerly called carcinoids) can show glandular growth pattern 
(56, 57) and mucin positivity (58). Since the gastric carcinomas 
with endocrine differentiation (which mainly are of diffuse type), 
more specifically seem to be of ECL cell origin (59), the principal 
regulator of ECL cell function as well as growth, gastrin, naturally 
becomes of central interest in gastric carcinogenesis.
GASTRiN AND GASTRiC NeTs
More than 30 years ago, gastrin was realized to induce gastric 
NETs in man whether due to gastrinoma with increased 
gastric acid secretion (60) or being secondary to hypoacidity 
4Waldum et al. Gastrin and Gastric Cancer
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(61) causing Bordi to raise the question whether this was a 
hormone induced tumor (62). These tumors were regarded as 
rather benign and also very rare. Gastric NETs were therefore 
not seen as very important from a clinical point of view. With 
the description of NETs in the oxyntic mucosa of rodents dosed 
long term with inhibitors of gastric acid secretion belonging to 
the histamine receptor-2 blockers (H-2 blockers) like loxtidine 
(63) or the proton pump inhibitors (PPIs) omeprazole (64), the 
interest increased dramatically since these drug were so com-
monly used. It was soon realized that hypergastrinemia was the 
common pathogenic factor and that the degree and duration 
of hypoacidity and secondary hypergastrinemia determine the 
risk of tumor development. Thus, although very high doses of 
the commonly used H-2 blockers like ranitidine can induce 
such tumors in rodents (65), the doses used clinically carry little 
risk since the potency of H-2 blockers in clinical use is too low. 
Moreover, the tolerance ordinary H-2 blockers induce (66) also 
protects against long-term marked hypoacidity/hypergastrine-
mia. Loxtidine was the so-called unsurmountable H-2 blocker 
(63), and this compound was not developed into a drug due 
to the NETs seen in rodents. The PPIs are very efficient drugs 
in inhibiting gastric acid secretion (67), but at the same time 
risky due to hypergastrinemia. Rather early, it was shown that 
PPI treatment induced ECL cell hyperplasia (68), which caused 
rebound acid hypersecretion (69). A decade later, it was reported 
that a period of PPI dosed to healthy individuals induced dys-
pepsia (70) probably due to rebound acid hypersecretion. Studies 
based on treatment of PPIs for up to 10 years have not reported 
occurrence of gastric NETs (71, 72), and thus such treatment 
has therefore been claimed to be safe with regard to neoplasia. 
However, it has to be remembered that neoplasia and particularly 
with respect to tumors originating from NE cells, which are 
so slow proliferators, may take decades to develop. Moreover, 
already more than 15 years ago, the producer reported on the 
occurrence of reversible ECL cell NETs during omeprazole treat-
ment (73), and we (74) and others (75, 76) have reported similar 
tumors during PPI treatment. Finally, and very importantly, 
a large kindred from Spain was reported to develop ECL cell 
tumors of different degree of malignancy at a young age (20s 
and 30s) due to missense mutation causing lack of function of 
the proton pump. Thus, the homozygote individuals who all 
developed tumors had been anacidic and hypergastrinemic from 
birth (46). Most of the tumors were classified as NETs although 
one tumor was diagnosed as an adenocarcinoma (46). Later, 
we have examined these tumors and have concluded that the 
adenocarcinoma more correctly should have been classified as 
a NE neoplasm (47). We have also described a gastric NE carci-
noma that developed after about 12 years of PPI treatment (77). 
Oxyntic gastric neoplasia has been reported in all conditions 
with hypergastrinemia in animals as well as man. It is therefore 
no doubt that hypergastrinemia may lead to gastric NETs. The 
dominating role of gastrin in the pathogenesis of gastric NETs 
is demonstrated by their eradication by the treatment with the 
gastrin antagonist netazepide (78). We have also demonstrated 
that treatment with a long-acting somatostatin analog makes 
gastric NETs disappear or shrink (79). This effect was most prob-
ably due to a direct effect on the tumor cells since the reduction 
in blood gastrin was only marginal (79). On the other hand, 
patients operated with antrectomi due to peptic ulcer either 
as Billroth-I or particularly Billroth-II do develop after long 
latency carcinomas in the remnant stomach even though they 
are hypogastrinemic (80). However, not only the ECL cell but 
also other NE cells in the gastric mucosa could possibly give rise 
to tumors. Thus, we have described a case where a cancer of the 
remnant stomach originating from the D cell, developed decades 
after the Billroth-II procedure (81). It has not yet been examined, 
but it is conceivable that gastrin has a negative trophic effect on 
the D cell in the oxyntic mucosa.
GASTRiN AND GASTRiC CARCiNOMAS
The main cause of gastric carcinomas is Hp infection (31) and 
mainly when inducing atrophy of the oxyntic mucosa (36). 
Atrophic oxyntic gastritis leads to reduced acid secretion, gastric 
hypoacidity, and secondary hypergastrinemia (26). We have 
repeatedly shown that gastric carcinomas, especially of diffuse 
type, express NE markers (54, 55) and more specifically ECL cell 
markers (59), which incriminate gastrin in the pathogenesis. We 
have described a patient with pernicious anemia who developed a 
gastric NET that was removed endoscopically and after 1 year had 
recurrence of the tumor, resulting in gastrectomy and who died 
some years later of general metastasis (82). During the 5-year 
period after the first diagnosis of the gastric NET, the tumor 
showed progressive loss of NE markers and a dramatic increase 
in proliferation demonstrating the transition from a gastric NET 
into a highly malignant carcinoma (82). The close relationship 
between gastric NETs and gastric carcinomas is also reflected 
by the co-occurrence of NETs and carcinomas in autoimmune 
gastritis (83) as well as Hp gastritis predisposing both to gastric 
cancer (31) and gastric NETs (43). A few studies have reported 
hypergastrinemia in patients with gastric carcinoma (84–86). 
The gastric carcinomas of diffuse type quite possibly originate 
from the ECL cell (54, 55, 59) by dedifferentiation. Carcinomas 
of intestinal type are also associated to atrophic oxyntic gastritis 
(87), but this type of gastric carcinoma more seldom express 
NE markers and therefore more likely develop from the stem 
cells. However, gastrin may nevertheless be important in the 
carcinogenic process leading to carcinoma of intestinal type by 
stimulating the proliferation of the stem cell, either by a possible 
but not proven gastrin receptor on this cell or indirectly by a posi-
tive trophic effect of mediators from the ECL cell, among them 
Reg protein is the most likely candidate (88) (Figure 2).
Since the acknowledgment of the central role of Hp infection 
in gastric carcinogenesis (31), there has been an unsuccessful 
search for the mechanism. However, it seems logical to focus on 
the gastritis since also the so-called autoimmune gastritis predis-
poses to gastric cancer (33). Moreover, oxyntic gastric atrophy 
is a common feature in conditions causing gastric cancer (36), 
and therefore, we recently proposed that hypergastrinemia could 
be the factor incriminated in Hp gastric carcinogenesis (89). The 
risk of long-term profound inhibition of gastric acid secretion 
particularly by the very efficient PPIs is increasingly recognized 
(90, 91). To conclude this part, gastrin seems to be the most 
important factor in gastric carcinogenesis.
FiGURe 2 | The way hypergastrinemia may induce gastric carcinoma 
of both diffuse and intestinal types [from waldum et al. (89) with 
permission].
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CONSeQUeNCeS OF THe DOMiNATiNG 
ROLe OF GASTRiN iN GASTRiC 
CARCiNOGeNeSiS
The understanding of the fundamental role of gastrin in gastric 
carcinogenesis is of clinical importance. Thus, we should avoid 
long-term treatment particularly in children and young adults 
due to their long life expectancy, with inhibitors of gastric secre-
tion leading to hypergastrinemia. Presently, long-term treatment 
with PPI is mainly indicated in patients with gastroesophageal 
reflux disease (GERD). In young GERD patients, H-2 blocker 
treatment should be the first choice in order to reach the goals 
(acceptable symptomatic relief and healing of lesions) at the 
lowest level of acid inhibition as possible. The alternative of anti-
reflux surgery must also be carefully evaluated in these patients. 
When PPI treatment is applied, gastrin and chromogranin A, 
which in this setting are good markers of the ECL cell mass (22, 
69, 92), should be monitored. It may in the future be possible to 
treat young patients with oxyntic atrophic gastritis and hypergas-
trinemia with a gastrin antagonist as prophylaxis against cancer. 
Furthermore, at which stage of tumor development gastrin loses 
its effect must be elucidated, in order to determine whether a 
gastrin antagonist could be used in the treatment. Indirectly, this 
may be assessed by examination of the tumor cells for the pres-
ence of the gastrin receptor either by immunohistochemistry or 
by in situ hybridization.
CONCLUSiON
Gastrin and its target cell, the ECL cell, probably play a central 
role in gastric carcinogenesis.
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